MicroRNAs, wild-typeand mutant p53: More questions than answers

RNA Biology

Volumn 9, Issue 6, 2012, Pages 781-791

  Jones, Matthew Fletcher ^a   Lal, Ashish ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; MiRNA; miRNA dysregulation; Mutant p53; p53; Wild type p53

Indexed keywords

MICRORNA; MICRORNA 107; MICRORNA 1204; MICRORNA 1205; MICRORNA 1206; MICRORNA 1207 3P; MICRORNA 1207 5P; MICRORNA 1208; MICRORNA 122; MICRORNA 125B; MICRORNA 141; MICRORNA 143; MICRORNA 145; MICRORNA 192; MICRORNA 194; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 206; MICRORNA 215; MICRORNA 25; MICRORNA 29; MICRORNA 30D; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; MICRORNA 429; MICRORNA 504; MICRORNA 605; PROTEIN P53; UNCLASSIFIED DRUG; MUTANT PROTEIN; TP53 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ACETYLATION; APOPTOSIS; BIOGENESIS; BREAST CANCER; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CELL CYCLE ARREST; CELL DEATH; CELL FATE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DNA DAMAGE; DNA STRUCTURE; EPITHELIAL MESENCHYMAL TRANSITION; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE LOCUS; GENE OVEREXPRESSION; GENE REPRESSION; GENOTOXICITY; HUMAN; IONIZING RADIATION; MATRIX ATTACHMENT REGION; NUCLEAR LOCALIZATION SIGNAL; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; RNA CLEAVAGE; RNA SPLICING; RNA TRANSCRIPTION; TUMOR GROWTH; UBIQUITINATION; UPREGULATION; ANIMAL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE; RNA PROCESSING;

EUKARYOTA;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MUTANT PROTEINS; RNA INTERFERENCE; RNA PROCESSING, POST-TRANSCRIPTIONAL; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863488058     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.20146     Document Type: Review

References (156)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-11; PMID:9486653; http://dx.doi.org/10.1038/35888.
2. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843-54; PMID:8252621; http://dx.doi.org/10.1016/0092-8674(93)90529-Y.
3. Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet 2009; 10:94-108; PMID:19148191; http://dx.doi.org/10.1038/nrg2504.
4. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5:522-31; PMID:15211354; http://dx.doi.org/10. 1038/nrg1379.
5. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle 2005; 4:1179-84; PMID:16096373; http://dx.doi.org/10.4161/cc.4.9.2032.
6. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007; 23:175-205; PMID:17506695; http://dx.doi.org/10.1146/annurev.cellbio.23.090506. 123406.
7. Ambros V. The functions of animal microRNAs. Nature 2004; 431:350-5; PMID:15372042; http://dx.doi.org/10.1038/nature02871.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 2004; 116:281-97; PMID:14744438; http://dx.doi.org/10.1016/S0092-8674(04)00045- 5.
9. Berezikov E. Evolution of microRNA diversity and regulation in animals. Nat Rev Genet 2011; 12:846-60; PMID:22094948; http://dx.doi.org/10.1038/nrg3079.
10. Rigoutsos I. Short RNAs: how big is this iceberg? Current biology: CB 2010; 20:110-3.
11. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009; 10:126-39; PMID:19165215; http://dx.doi.org/10.1038/nrm2632.
12. Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008; 455:64-71; PMID:18668037; http://dx.doi.org/10.1038/nature07242.
13. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19:92-105; PMID:18955434; http://dx.doi.org/10.1101/gr.082701.108.
14. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:15-20; PMID:15652477; http://dx.doi.org/10.1016/j.cell.2004.12.035.
15. Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008; 455:58-63; PMID:18668040; http://dx.doi.org/10.1038/nature07228.
16. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37:495-500; PMID:15806104; http://dx.doi.org/10.1038/ng1536.
17. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432:307-15; PMID:15549092; http://dx.doi.org/10.1038/nature03098.
18. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4:793-805; PMID:15510160; http://dx.doi.org/10.1038/ nrc1455.
19. Braithwaite AW, Prives CL. p53: more research and more questions. Cell Death Differ 2006; 13:877-80; PMID:16708075; http://dx.doi.org/10.1038/sj.cdd. 4401938.
20. Junttila MR, Evan GI. p53 - a Jack of all trades but master of none. Nat Rev Cancer 2009; 9:821-9; PMID:19776747; http://dx.doi.org/10.1038/nrc2728.
21. Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009; 9:714-23; PMID:19730431.
22. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2:594-604; PMID:12154352; http://dx.doi.org/10.1038/nrc864.
23. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer 2009; 9:724-37; PMID:19776742; http://dx.doi.org/10.1038/nrc2730.
24. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-12; PMID:18431400; http://dx.doi.org/10.1038/nrm2395.
25. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10; PMID:11099028; http://dx.doi.org/10.1038/35042675.
26. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275-83; PMID:17380161; http://dx.doi.org/10.1038/nrm2147.
27. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413-31; PMID:19410540; http://dx.doi.org/10.1016/j.cell. 2009.04.037.
28. McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K, et al. p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle 2010; 9:4200-12; PMID:20962589; http://dx.doi.org/10.4161/cc.9.20.13532.
29. Spurgers KB, Gold DL, Coombes KR, Bohnenstiehl NL, Mullins B, Meyn RE, et al. Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem 2006; 281:25134-42; PMID:16798743; http://dx.doi.org/10.1074/jbc.M513901200.
30. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999; 13:2490-501; PMID:10521394; http://dx.doi.org/10.1101/gad.13.19.2490.
31. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005; 6:376-85; PMID:15852042; http://dx.doi.org/10.1038/nrm1644.
32. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004; 14:1902-10; PMID:15364901; http://dx.doi.org/10.1101/gr.2722704.
33. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 2002; 21:4663-70; PMID:12198168; http://dx.doi.org/10.1093/emboj/cdf476.
34. Han J, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell 2006; 125:887-901; PMID:16751099; http://dx.doi.org/10.1016/j.cell.2006.03.043.
35. Czech B, Hannon GJ. Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet 2011; 12:19-31; PMID:21116305; http://dx.doi.org/10.1038/nrg2916.
36. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115:209-16; PMID:14567918; http://dx.doi.org/10.1016/ S0092-8674(03)00801-8.
37. Brodersen P, Voinnet O. Revisiting the principles of microRNA target recognition and mode of action. Nat Rev Mol Cell Biol 2009; 10:141-8; PMID:19145236; http://dx.doi.org/10.1038/nrm2619.
38. Djuranovic S, Nahvi A, Green R. A parsimonious model for gene regulation by miRNAs. Science 2011; 331:550-3; PMID:21292970; http://dx.doi.org/10.1126/ science.1191138.
39. Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O'Day E, et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC and other cell cycle genes via binding to "seedless" 3′ UTR microRNA recognition elements. Mol Cell 2009; 35:610-25; PMID:19748357; http://dx.doi.org/10.1016/j.molcel. 2009.08.020.
40. Shin C, Nam JW, Farh KK, Chiang HR, Shkumatava A, Bartel DP. Expanding the microRNA targeting code: functional sites with centered pairing. Mol Cell 2010; 38:789-802; PMID:20620952; http://dx.doi.org/10.1016/j.molcel.2010.06.005.
41. Chi SW, Hannon GJ, Darnell RB. An alternative mode of microRNA target recognition. Nat Struct Mol Biol 2012; 19:321-7; PMID:22343717; http://dx.doi.org/10.1038/nsmb.2230.
42. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215-33; PMID:19167326; http://dx.doi.org/10.1016/j.cell.2009.01.002.
43. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009; 136:642-55; PMID:19239886; http://dx.doi.org/10.1016/j.cell.2009.01. 035.
44. Thomas M, Lieberman J, Lal A. Desperately seeking microRNA targets. Nat Struct Mol Biol 2010; 17:1169-74; PMID:20924405; http://dx.doi.org/10.1038/nsmb. 1921.
45. Chi SW, Zang JB, Mele A, Darnell RB. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 2009; 460:479-86; PMID:19536157.
46. Forman JJ, Coller HA. The code within the code: microRNAs target coding regions. Cell Cycle 2010; 9:1533-41; PMID:20372064; http://dx.doi.org/10.4161/ cc.9.8.11202.
47. Forman JJ, Legesse-Miller A, Coller HA. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. Proc Natl Acad Sci USA 2008; 105:14879-84; PMID:18812516; http://dx.doi.org/10.1073/pnas.0803230105.
48. Lee EK, Gorospe M. Coding region: the neglected post-transcriptional code. RNA Biol 2011; 8:44-8; PMID:21289484; http://dx.doi.org/10.4161/rna.8.1. 13863.
49. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008; 455:1124-8; PMID:18806776; http://dx.doi.org/10.1038/nature07299.
50. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466:835-40; PMID:20703300; http://dx.doi.org/10.1038/nature09267.
51. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010; 79:351-79; PMID:20533884; http://dx.doi.org/10.1146/annurev-biochem-060308-103103.
52. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10:704-14; PMID:19763153; http://dx.doi.org/10.1038/nrg2634.
53. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-69; PMID:16557279; http://dx.doi.org/10.1038/nrc1840.
54. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12:861-74; PMID:22094949; http://dx.doi.org/10.1038/nrg3074.
55. Hammond SM. MicroRNAs as tumor suppressors. Nat Genet 2007; 39:582-3; PMID:17460676; http://dx.doi.org/10.1038/ng0507-582.
56. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449:682-8; PMID:17898713; http://dx.doi.org/10.1038/nature06174.
57. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12:247-56; PMID:20173740.
58. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs - the micro steering wheel of tumour metastases. Nat Rev Cancer 2009; 9:293-302; PMID:19262572; http://dx.doi.org/10.1038/nrc2619.
59. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451:147-52; PMID:18185580; http://dx.doi.org/10.1038/nature06487.
60. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137:1032-46; PMID:19524507; http://dx.doi.org/10.1016/j. cell.2009.03.047.
61. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009; 136:586-91; PMID:19239879; http://dx.doi.org/10.1016/j.cell.2009.02.005.
62. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99:15524-9; PMID:12434020; http://dx.doi.org/10.1073/pnas.242606799.
63. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17:28-40; PMID:20060366; http://dx.doi.org/10.1016/j.ccr.2009.11.019.
64. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101:11755-60; PMID:15284443; http://dx.doi.org/10.1073/pnas.0404432101.
65. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-66; PMID:17060945; http://dx.doi.org/10.1038/nrc1997.
66. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8; PMID:15944708; http://dx.doi.org/10.1038/nature03702.
67. Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, Calin GA, et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet 2009; 41:365-70; PMID:19219043; http://dx.doi.org/10.1038/ ng.317.
68. Hill DA, Ivanovich J, Priest JR, Gurnett CA, Dehner LP, Desruisseau D, et al. DICER1 mutations in familial pleuropulmonary blastoma. Science 2009; 325:965; PMID:19556464; http://dx.doi.org/10.1126/science.1174334.
69. Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R, et al. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 2010; 18:303-15; PMID:20951941; http://dx.doi.org/10.1016/j. ccr.2010.09.007.
70. West JA, Viswanathan SR, Yabuuchi A, Cunniff K, Takeuchi A, Park IH, et al. A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature 2009; 460:909-13; PMID:19578360.
71. Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2012; 31:2062-74; PMID:21874049.
72. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006; 9:435-43; PMID:16766263; http://dx.doi.org/10.1016/j.ccr.2006.04.020.
73. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40:43-50; PMID:18066065; http://dx.doi.org/10.1038/ng.2007.30.
74. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435:839-43; PMID:15944709; http://dx.doi.org/10.1038/nature03677.
75. Chang TC, Zeitels LR, Hwang HW, Chivukula RR, Wentzel EA, Dews M, et al. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci USA 2009; 106:3384-9; PMID:19211792; http://dx.doi.org/10.1073/pnas.0808300106.
76. Bui TV, Mendell JT. Myc: Maestro of MicroRNAs. Genes & cancer 2010; 1:568-75.
77. Emmrich S, Pützer BM. Checks and balances: E2F-microRNA crosstalk in cancer control. Cell Cycle 2010; 9:2555-67; PMID:20581444; http://dx.doi.org/ 10.4161/cc.9.13.12061.
78. Woods K, Thomson JM, Hammond SM. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem 2007; 282:2130-4; PMID:17135268; http://dx.doi.org/10.1074/jbc.C600252200.
79. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer? EMBO Rep 2010; 11:670-7; PMID:20706219; http://dx.doi.org/10.1038/embor.2010.117.
80. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11:1487-95; PMID:19935649; http://dx.doi.org/10. 1038/ncb1998.
81. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Current biology 2007; 17:1298-307. (Pubitemid 47176893)
82. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26:745-52; PMID:17540599; http://dx.doi.org/10.1016/j.molcel.2007.05.010.
83. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network - another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007; 7:819-22; PMID:17914404; http://dx.doi.org/10.1038/nrc2232.
84. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26:731-43; PMID:17540598; http://dx.doi.org/10.1016/j. molcel.2007.05.017.
85. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-inducible microRNAs 192, 194 and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18:367-81; PMID:20951946; http://dx.doi.org/10.1016/j.ccr.2010.09.005.
86. Xiao J, Lin H, Luo X, Luo X, Wang Z. miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J 2011; 30:524-32; PMID:21217645; http://dx.doi.org/10.1038/emboj.2010.347.
87. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105:13421-6; PMID:18755897; http://dx.doi.org/10.1073/pnas.0801613105.
88. Hermeking H. p53 enters the microRNA world. Cancer Cell 2007; 12:414-8; PMID:17996645; http://dx.doi.org/10.1016/j.ccr.2007.10.028.
89. Hermeking H. MiR-34a and p53. Cell Cycle 2009; 8:1308; PMID:19342875; http://dx.doi.org/10.4161/cc.8.9.8511.
90. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006; 124:207-19; PMID:16413492; http://dx.doi.org/10.1016/j.cell.2005.10.043.
91. Giono LE, Manfredi JJ. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 2006; 209:13-20; PMID:16741928; http://dx.doi.org/10.1002/jcp.20689.
92. Lal A, Thomas MP, Altschuler G, Navarro F, O'Day E, Li XL, et al. Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet 2011; 7:1002363; PMID:22102825; http://dx.doi.org/10.1371/journal.pgen.1002363.
93. Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol 2011; 195:417-33; PMID:22024162; http://dx.doi.org/10.1083/jcb. 201103097.
94. Navarro F, Gutman D, Meire E, Cáceres M, Rigoutsos I, Bentwich Z, et al. miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53. Blood 2009; 114:2181-92; PMID:19584398; http://dx.doi.org/10.1182/blood-2009-02-205062.
95. Sotillo E, Laver T, Mellert H, Schelter JM, Cleary MA, McMahon S, et al. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 2011; 30:2587-94; PMID:21297663; http://dx.doi.org/10.1038/onc.2010. 634.
96. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22:894-907; PMID:18381893; http://dx.doi.org/10.1101/ gad.1640608.
97. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593-601; PMID:18376396; http://dx.doi.org/10.1038/ncb1722.
98. Korpal M, Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008; 5:115-9; PMID:19182522; http://dx.doi.org/10.4161/rna.5.3.6558.
99. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13:317-23; PMID:21336307; http://dx.doi.org/10.1038/ ncb2173.
100. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S, et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011; 208:875-83; PMID:21518799; http://dx.doi.org/10.1084/jem. 20110235.
101. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011; 17:1101-8; PMID:21822286; http://dx.doi.org/10.1038/nm.2401.
102. Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 2009; 4:7181; PMID:19787069; http://dx.doi.org/10.1371/journal.pone.0007181.
103. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008; 68:10094-104; PMID:19074875; http://dx.doi.org/10.1158/0008- 5472.CAN-08-1569.
104. Böhlig L, Friedrich M, Engeland K. p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins. Nucleic Acids Res 2011; 39:440-53; PMID:20833636; http://dx.doi.org/10.1093/nar/gkq796.
105. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 2010; 107:6334-9; PMID:20308559; http://dx.doi.org/10.1073/pnas. 0911082107.
106. Huppi K, Volfovsky N, Runfola T, Jones TL, Mackiewicz M, Martin SE, et al. The identification of microRNAs in a genomically unstable region of human chromosome 8q24. Mol Cancer Res 2008; 6:212-21; PMID:18314482; http://dx.doi.org/10.1158/1541-7786.MCR-07-0105.
107. Barsotti AM, Beckerman R, Laptenko O, Huppi K, Caplen NJ, Prives C. p53-Dependent induction of PVT1 and miR-1204. J Biol Chem 2012; 287:2509-19; PMID:22110125; http://dx.doi.org/10.1074/jbc.M111.322875.
108. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103:2257-61; PMID:16461460; http://dx.doi.org/10. 1073/pnas.0510565103.
109. Chen L, Li C, Zhang R, Gao X, Qu X, Zhao M, et al. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett 2011; 309:62-70; PMID:21664042; http://dx.doi.org/10.1 016/j.canlet.2011.05.017.
110. Yan HL, Xue G, Mei Q, Wang YZ, Ding FX, Liu MF, et al. Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J 2009; 28:2719-32; PMID:19696742; http://dx.doi.org/10.1038/emboj.2009. 214.
111. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67:7713-22; PMID:17699775; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-1083.
112. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131:1109-23; PMID:18083101; http://dx.doi.org/10.1016/j.cell.2007.10.054.
113. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007; 67:11111-6; PMID:18056433; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-2858.
114. Saleh AD, Savage JE, Cao L, Soule BP, Ly D, DeGraff W, et al. Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53. PLoS One 2011; 6:24429; PMID:22022355; http://dx.doi.org/10. 1371/journal.pone.0024429.
115. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005; 6:44-55; PMID:15688066; http://dx.doi.org/10.1038/nrm1546.
116. Riley KJ, Maher LJ, 3rd. p53 RNA interactions: new clues in an old mystery. RNA 2007; 13:1825-33; PMID:17804642; http://dx.doi.org/10.1261/rna. 673407.
117. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009; 460:529-33; PMID:19626115; http://dx.doi.org/10.1038/nature08199.
118. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2 and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009; 137:647-58; PMID:19409607; http://dx.doi.org/10.1016/j.cell. 2009.02.038.
119. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J 2009; 276:6689-700; PMID:19843160; http://dx.doi.org/10.1111/j.1742-4658.2009.07383.x.
120. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to downregulation of the tumor suppressor protein PDCD4, anti-apoptosis and chemotherapy resistance in breast tumor cells. J Biol Chem 2009; 284:26533-46; PMID:19633292; http://dx.doi.org/10.1074/jbc.M109.027466.
121. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008; 454:56-61; PMID:18548003; http://dx.doi.org/10.1038/nature07086.
122. Yamagata K, Fujiyama S, Ito S, Ueda T, Murata T, Naitou M, et al. Maturation of microRNA is hormonally regulated by a nuclear receptor. Mol Cell 2009; 36:340-7; PMID:19854141; http://dx.doi.org/10.1016/j.molcel.2009.08.017.
123. Le MT, The C, Shyh-Chang N, Xie H, Zhou B, Korzh V, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009; 23:862-76; PMID:19293287; http://dx.doi.org/10.1101/gad.1767609.
124. Le MT, Shyh-Chang N, Khaw SL, Chin L, The C, Tay J, et al. Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNAtarget gene pairs. PLoS Genet 2011; 7:1002242; PMID:21935352; http://dx.doi.org/10.1371/journal.pgen.1002242.
125. Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song JS, et al. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell 2010; 38:689-99; PMID:20542001; http://dx.doi.org/10.1016/j.molcel.2010.05.027.
126. Kumar M, Lu Z, Takwi AA, Chen W, Callander NS, Ramos KS, et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011; 30:843-53; PMID:20935678; http://dx.doi.org/10.1038/onc.2010.457.
127. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006; 34:140-4; PMID:16381832; http://dx.doi.org/10.1093/nar/gkj112.
128. Chen QR, Yu LR, Tsang P, Wei JS, Song YK, Cheuk A, et al. Systematic proteome analysis identifies transcription factor YY1 as a direct target of miR-34a. J Proteome Res 2011; 10:479-87; PMID:21182263; http://dx.doi.org/10. 1021/pr1006697.
129. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107:137-48; PMID:11672522; http://dx.doi.org/10.1016/S0092-8674(01)00524-4.
130. Sui G, Affarel B, Shi Y, Brignone C, Wall NR, Yin P, et al. Yin Yang 1 is a negative regulator of p53. Cell 2004; 117:859-72; PMID:15210108; http://dx.doi.org/10.1016/j.cell.2004.06.004.
131. Choi J, Nannenga B, Demidov ON, Bulavin DV, Cooney A, Brayton C, et al. Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function and cell cycle control. Mol Cell Biol 2002; 22:1094-105; PMID:11809801; http://dx.doi.org/10.1128/MCB.22.4.1094- 105.2002.
132. Zhang X, Wan G, Mlotshwa S, Vance V, Berger FG, Chen H, et al. Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res 2010; 70:7176-86; PMID:20668064; http://dx.doi.org/10.1158/0008-5472. CAN-10-0697.
133. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85alpha and CDC42. Nat Struct Mol Biol 2009; 16:23-9; PMID:19079265; http://dx.doi.org/10.1038/nsmb.1533.
134. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009; 69:5761-7; PMID:19584283; http://dx.doi.org/10.1158/0008-5472.CAN-08-4797.
135. Burns DM, D'Ambrogio A, Nottrott S, Richter JD. CPEB and two poly(A) polymerases control miR-122 stability and p53 mRNA translation. Nature 2011; 473:105-8; PMID:21478871; http://dx.doi.org/10.1038/nature09908.
136. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011; 192:209-18; PMID:21263025; http://dx.doi.org/10.1083/jcb.201009059.
137. Liu Y, Bodmer WF. Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci USA 2006; 103:976-81; PMID:16418264; http://dx.doi.org/10.1073/pnas.0510146103.
138. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9:701-13; PMID:19693097.
139. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2:1107; PMID:20182618; http://dx.doi.org/10.1101/ cshperspect.a001107.
140. Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006; 10:437-49; PMID:17097565; http://dx.doi.org/10. 1016/j.ccr.2006.09.013.
141. Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 2009; 16:1086-93; PMID:19783986; http://dx.doi.org/10.1038/nsmb.1669.
142. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010; 17:273-85; PMID:20227041; http://dx.doi.org/10.1016/j.ccr. 2009.11.025.
143. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006; 10:191-202; PMID:16959611; http://dx.doi.org/10.1016/j.ccr.2006.08. 013.
144. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 downregulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 2001; 21:1874-87; PMID:11238924; http://dx.doi.org/10.1128/MCB.21.5.1874-87.2001.
145. Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007; 26:2220-5; PMID:17401431; http://dx.doi.org/10.1038/sj.onc.1210311.
146. Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D, et al. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J 2001; 20:4163-72; PMID:11483519; http://dx.doi.org/10.1093/emboj/20.15.4163.
147. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M, et al. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 2004; 64:8318-27; PMID:15548700; http://dx.doi.org/10.1158/0008- 5472.CAN-04-1145.
148. Göhler T, Jäger S, Warnecke G, Yasuda H, Kim E, Deppert W. Mutant p53 proteins bind DNA in a DNA structure-selective mode. Nucleic Acids Res 2005; 33:1087-100; PMID:15722483; http://dx.doi.org/10.1093/nar/gki252.
149. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012; 19:1038-48; PMID:22193543.
150. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010; 467:986-90; PMID:20962848; http://dx.doi.org/10.1038/nature09459.
151. Mukherji S, Ebert MS, Zheng GX, Tsang JS, Sharp PA, van Oudenaarden A. MicroRNAs can generate thresholds in target gene expression. Nat Genet 2011; 43:854-9; PMID:21857679; http://dx.doi.org/10.1038/ng.905.
152. Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, et al. The microRNAs of Caenorhabditis elegans . Genes Dev 2003; 17:991-1008; PMID:12672692; http://dx.doi.org/10.1101/gad.1074403.
153. Leung AK, Sharp PA. MicroRNA functions in stress responses. Mol Cell 2010; 40:205-15; PMID:20965416; http://dx.doi.org/10.1016/j.molcel.2010.09.027.
154. Li X, Cassidy JJ, Reinke CA, Fischboeck S, Carthew RW. A microRNA imparts robustness against environmental fluctuation during development. Cell 2009; 137:273-82; PMID:19379693; http://dx.doi.org/10.1016/j.cell.2009.01.058.
155. Xu P, Vernooy SY, Guo M, Hay BA. The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Current biology: CB 2003; 13:790-5.
156. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136:823-37; PMID:19269363; http://dx.doi.org/10.1016/j.cell.2009.02.024.